These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38482279)

  • 41. Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey.
    Kaur S; Singh A; Saini S; Rohilla L; Kaur J; Chandi A; Kaur G; Singh M; Kumar P; Soni SL; Kajal K; Naik NB; Malhotra P; Verma S; Gupta M; Devnani M; Das K; Pandav SS; Puri GD
    Indian J Med Res; 2022 Jan; 155(1):123-128. PubMed ID: 35859438
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Study of immunogenicity, safety and efficacy of covishield vaccine among health care workers in a tertiary cardiac care centre.
    Mahadevaiah A; Doddamadaiah C; K S S; Cholenahalli Nanjappa M
    Indian J Med Microbiol; 2022; 40(2):200-203. PubMed ID: 35422343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. COVID-19 vaccination: Is it a matter of concern?
    Kushwaha P; Pundhir A; Gahlot A
    J Family Med Prim Care; 2022 Jun; 11(6):2431-2436. PubMed ID: 36119229
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse events associated with Covishield vaccination among healthcare workers in a tertiary hospital in South India.
    T Sathyapalan D; Moni M; Prasanna P; Marwaha V; Bala Madathil S; Edathadathil F; Jose SA; Pavithran S; Muralikrishanan R; Ramachandran N; P R R; T S T; Nair AS; Kuriachan S; Louis Palatty P
    Vaccine X; 2022 Dec; 12():100210. PubMed ID: 36059598
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies Among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 Vaccine.
    Vu DM; Vu DTB; Do TTT; Olmsted AE; Dao BH; Thai TT; Nguyen CL; Le NTT; Le TA; Bui HTT; Pham TN; Moore MR
    Clin Infect Dis; 2022 Oct; 75(Suppl 2):S174-S181. PubMed ID: 35723271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adverse Events Following the First Dose of Immunization of COVID-19 Vaccine.
    Bhandari B; Jha N; Khan IH; Rayamajhi G; Thapa L; Bista B
    J Nepal Health Res Counc; 2022 Jun; 20(1):59-64. PubMed ID: 35945854
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A study on seroconversion following first & second doses of ChAdOx1 nCoV-19 vaccine in Central Kerala.
    Varghese SM; Mateethra GC; George G; Chandran VS; John GM; Varghese LT; Mammen NK; Vinayak V
    Indian J Med Res; 2022; 155(5&6):499-504. PubMed ID: 36348597
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand.
    Mahasing C; Doungngern P; Jaipong R; Nonmuti P; Chimmanee J; Wongsawat J; Boonyasirinant T; Wanlapakorn C; Leelapatana P; Yingchoncharoen T; Ngarmukos T; Chokephaibulkit K; Srimahachota S
    Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112661
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adverse events following COVID-19 immunisation (AEFI) at a COVID-19 vaccination centre: An observational analytical study.
    Shukla V; Sachan B; Jauhari S; Bhardwaj S; Pathak A; Kandpal SD
    J Family Med Prim Care; 2023 Mar; 12(3):460-465. PubMed ID: 37122665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous orHeterologous COVID-19 Booster Vaccinations.
    Wei Y; Wang Y; Liu J; Zha Y; Yang Y; Li N; Zhou Y; Roberts JZN; Liu L; Li Y
    Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36366377
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions.
    Lee SW; Moon JY; Lee SK; Lee H; Moon S; Chung SJ; Yeo Y; Park TS; Park DW; Kim TH; Sohn JW; Yoon HJ; Kim SH
    Front Immunol; 2021; 12():779212. PubMed ID: 34899739
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Cross-Sectional Study to Assess mRNA-COVID-19 Vaccine Safety among Indian Children (5-17 Years) Living in Saudi Arabia.
    Ahsan M; Shaik RA; Mallick AK; Banawas SS; Alruwaili TAM; Alanazi YA; Alzahrani HS; Ahmad RK; Ahmad MS; AlAnazi FH; Alfhaid F; Aljulifi MZ; Mehta V; Almhmd AE; Daham ASDA; Alruwaili MMM
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851085
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccine Safety: Assessing the Prevalence and Severity of Adverse Events Following COVID-19 Vaccination amongst Healthcare Workers in Tertiary Health Facilities in Nigeria.
    Azees AS; Fasiku MM; Isa A; Ezenwoko AZ; Ahmed A; Temitayo-Oboh AO; Utulu R; Adeniyi MA; Musa A; Alo C; Ibrahim UM; Imhonopi GB; Adesoye OO; Okeke IM; John GT; Ayinla AY
    Niger Postgrad Med J; 2024 Jan; 31(1):1-7. PubMed ID: 38321791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Barriers to healthcare workers reporting adverse events following immunization in Zhejiang province, China.
    Lv H; Pan X; Wang Y; Liang H; Yu H
    Hum Vaccin Immunother; 2022 Nov; 18(5):2083865. PubMed ID: 35820038
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vaccine hesitancy after taking the first dose of COVID-19 vaccine: A challenge for the COVID-19 vaccination program in India.
    Bansal Y; Chand P; Bansal N; Singh P
    J Family Med Prim Care; 2022 May; 11(5):2201-2206. PubMed ID: 35800545
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence of COVID-19 Vaccine Side Effects among Early-Vaccinated Healthcare Workers in Eastern Ethiopia.
    Jarso G; Gebi W; Abdo M; Lemma M; Abebe E; Lemessa B; Deressa BT
    Ethiop J Health Sci; 2022 May; 32(3):473-484. PubMed ID: 35813681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.
    Paris C; Perrin S; Hamonic S; Bourget B; Roué C; Brassard O; Tadié E; Gicquel V; Bénézit F; Thibault V; Garlantézec R; Tattevin P
    Clin Microbiol Infect; 2021 Nov; 27(11):1699.e5-1699.e8. PubMed ID: 34265462
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post COVID-19 vaccination: AusVaxSafety survey participation and adverse events - a community-based regional Queensland study.
    Hamilton E; Oversby S; Kitchener S; Ratsch A
    Aust N Z J Public Health; 2022 Dec; 46(6):738-744. PubMed ID: 36190203
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Covishield
    Murali S; Sakthivel M; Pattabi K; Venkatasamy V; Thangaraj JWV; Shete A; Varghese AJ; Arjun J; Kumar CPG; Yadav PD; Sahay R; Majumdar T; Dudhmal M; Sivalingam A; Dhanapal SR; Durai Samy A; Radhakrishnan V; Muni Krishnaiah MM; Arunachalam S; Gandhi PMK; Govindasamy E; Chinnappan P; Sekar DPV; Marappan P; Pounraj E; Ganeshkumar P; Jagadeesan M; Narnaware M; Bedi GS; Kaur P; Murhekar M
    Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746578
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Occurrence of COVID-19 in priority groups receiving ChAdOx1 nCoV-19 coronavirus vaccine (recombinant): A preliminary analysis from north India.
    Kaur U; Bala S; Ojha B; Jaiswal S; Kansal S; Chakrabarti SS
    J Med Virol; 2022 Jan; 94(1):407-412. PubMed ID: 34491572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.